Other articles

cierre_orejuela_stroke

Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

The PRAGUE-17 has shown that left atrial appendage closure is not inferior to direct anticoagulants at long term to prevent major cardiovascular, neurological, or bleeding events. Moreover, procedures not related to prosthesis implantation saw significant reduction. The PRAGUE-17 was a randomized non-inferiority study comparing left atrial appendage closure (Watchman or Amulet) with direct anticoagulants (95%

AHA 2021 | PALACS: la pericardiotomía posterior izquierda mejora la FA post operatoria

AHA 2021 | PALACS: Posterior Left Pericardiotomy Improves Post-Procedural AF

Posterior left pericardiotomy for the prevention of atrial fibrillation during cardiac surgery seems to significantly reduce atrial fibrillation risk (AF) after procedure. The procedure consists of a 4-5 cm incision in the posterior pericardium to allow drainage of fluids and thrombi from the pericardium to the pleural cavity during postoperative period.  Patients receiving the incision during surgery

AMULET Die: Un nuevo estudio compara los dispositivos Watchman y Amulet y arroja nueva evidencia

AMULET IDE: New Research Compares WatchMan and Amulet Devices Providing New Evidence

Recently, at the TCT Congress results from the SWISS-APERO study comparing Watchman and Amulet devices were presented. Now, a new study, Amulet IDE—published in Circulation—, compared both devices on a large number of patients. Amulet IDE was designed to evaluate the safety and efficacy of dual-seal mechanism device Amulet compared with the Watchman (a widely

TCT 2021 | SWISS-APERO: diferencia en los leaks entre Amulet y Watchman

TCT 2021 | SWISS-APERO: Difference in Leaks between the Amulet and the Watchman

The Amplatzer Amulet (Abbott) achieves better left atrial appendage closure than the Watchman 2.5 and Watchman FLX (Boston Scientific) in patients with atrial fibrillation at risk of stroke. This imaging finding has not yet been associated with clinical adverse events.  This study called SWISS-APERO was presented at TCT 2021 and simultaneously published in Circulation. It

AMULET vs WATCHMAN. Los dispositivos de cierre de orejuela cabeza a cabeza

AMULET vs. WATCHMAN: Appendage Closure Devices, Head to Head

This research was designed to compare the double closure system of the AMULET device with the WATCHMAN (an evidence-backed proven device). In that context, to prevent stroke in patients with non-valvular atrial fibrillation, the Amplatzer AMULET device was non-inferior in both safety and efficacy compared with the WATCHMAN. Atrial appendage occlusion in itself improved with

Miocardiopatía hipertrófica: análisis de una serie histórica

Differences in American and European Atrial Fibrillation Guidelines

The recent publication of the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) guidelines provided an important update on multiple aspects of the management of atrial fibrillation (AF). However, these guidelines differ in terms of management and recommendation levels. As it might be expected, most differences arose in intermediate cases—both guidelines

ACC 2021 | LAAOS III: Cierre de orejuela durante una cirugía vascular central

ACC 2021 | LAAOS III: Appendage Closure During Central Vascular Surgery

According to the LAAOS III study, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in the New England Journal of Medicine (NEJM), patients with atrial fibrillation who undergo central vascular surgery for any other indication find benefit in appendage closure during said surgery. Using oral anticoagulation agents, patients undergoing appendage closure

DEFENSE-PFO: el cierre FOP con ciertas características disminuye eventos combinados y stroke

Five-Years After PFO Closure: Procedural Safety and Effectiveness

Five-year outcomes of the randomized REDUCE study showed a continuous benefit from patent foramen ovale (PFO) closure compared with antiplatelet agents to prevent cryptogenic strokes. The most important aspect of this result seems to be the idea that PFO closure in selected patients offers durable benefit with guaranteed long-term safety. The original results from REDUCE

Boletín 116: Cierre Percutáneo del Foramen Oval Permeable

Bulletin 116 ProEducar | Percutaneous Closure of Patent Foramen Ovale

A new edition of the ProEducar Educational Bulletin has arrived for Fellows and interventionists in training. On this occasion, this bulletin addresses in depth the Percutaneous Closure of the Patent Foramen Ovale.   Discover the ProEducar Educational Bulletin HERE (spanish version)

ESC 2020 | Guías de Fibrilación Auricular 2020: Novedades sobre diagnóstico, clasificación y tratamiento

ESC 2020 | 2020 Atrial Fibrillation Guidelines: News on Diagnosis, Classification, and Care

New guidelines for the diagnosis and treatment of atrial fibrillation (AF) were released at the 2020 European Society of Cardiology (ESC) virtual congress. This document incorporates several findings from the latest clinical trials, but also represents a great shift in terms of how physicians from different specialties should classify and manage arrhythmia after confirming the

ESC 2020 | Guías de Fibrilación Auricular 2020: Novedades sobre diagnóstico, clasificación y tratamiento

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and symptoms. Mavacamten is the first myosin inhibitor drug of its class. Presented virtually at the European Society of Cardiology 2020 Congress (ESC 2020) and published simultaneously in The Lancet, the EXPLORER-HCM study showed that 37% of patients who received

Top